[ad_1] UnitedHealth is worth buying as it still trades at a cheap valuation coming out of a good earnings report, according to Bernstein. Analyst Lance Wilkes upgraded the health insurance stock to outperform from market perform and raised his price target by $8 to $603. His new target implies shares could rise 24.6% over the…
[ad_1] Representatives speak with customers at a UnitedHealthcare store in Queens, New York. Michael Nagle | Bloomberg | Getty Images UnitedHealth Group’s stock price jumped Friday after the health-care conglomerate reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations despite rising medical costs. The results eased investor concerns after the Minnesota-based company flagged…
[ad_1] Investors hoping to capture more upside from artificial intelligence could turn to a sector that’s underperformed this year, and maybe not immediately associated with AI: Health care. A handful of large tech names surged in the first half thanks to a mania for all things tied to artificial intelligence. Apple, for example, last week…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. Book profits on big winners Emerson catches an upgrade Humana shares stabilize 1. Book profits on big winners Wall Street climbed Thursday, led by an over 350-point, or roughly…
[ad_1] Health insurer stocks dropped Wednesday after UnitedHealth Group warned of higher medical costs as older Americans start to catch up on surgeries they delayed during the Covid-19 pandemic. Shares of UnitedHealth, the largest U.S. health-care provider by market value, closed around 6% lower. Medicare-focused insurer Humana declined 11%. Elevance Health closed roughly 7% lower,…
[ad_1] UnitedHealth Group has the highest price per share of any company on the Dow Jones Industrial Average and it’s the tenth heaviest-weighted stock on the S&P 500. In fact, not only is UnitedHealth the biggest health-care conglomerate in the United States based on market cap and revenue, it’s even bigger than JPMorgan Chase, the…
[ad_1] In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images News | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate…
